ZDHHC3

Across TCGA pan-cancer cohorts, ZDHHC3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZDHHC3 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZDHHC3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZDHHC3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, LUAD, and GBM are the cancer types where ZDHHC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.881	0.691	.016	14	view →
LUAD	OS	Tertile	II,III,IV	0.483	0.828	.019	8	view →
GBM	OS	Median	All	0.976	0.791	.047	1	view →
CCRCC	OS	Quartile	All	0.549	1.000	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZDHHC3–HNSC (DFS)

Open the HNSC breakdown →